I assume that most of the old-timers don't post on this site for one reason or another and I include myself in that group. However, I made a promise to Susan (myman) that I would post one more time, about a clinical trial I am about to join, in the hope that someone else here may benefit from it.

The drug, Sprycel (generic name tasatinib) is made by Bristol-Myers Squibb (BMS). It has shown great success in chronic myelogenous leukemia (CML) patients who no longer respond to the old standard Gleevec and BMS thinks/hopes it will be effective against solid tumors and is apparently starting with hormone refractory PCa. Sprycel is a tablet which is taken at home every day and is given in conjunction with Taxotere infusions given every twenty-one days.

Wikipedia and Google speak mostly to Sprycel vs. CML, but the number of Sprycel vs. PCa links seems to be growing.

The lead doctor is John C. Araujo, MD, PhD, my doc at M.D. Anderson in Houston, but, the trial is being conducted at a number of hospitals around the country.